ABCA1¹¹ ATP-Binding Cassette Transporter A1 — a cell-membrane pump that loads cholesterol and phospholipids onto lipid-poor apolipoprotein A-I, forming nascent HDL particles is the primary gatekeeper of reverse cholesterol transport²² reverse cholesterol transport
the pathway by which peripheral tissues offload excess cholesterol back to the liver for processing and excretion. Without ABCA1, cells cannot shed excess cholesterol and HDL formation collapses. Loss-of-function mutations in both copies cause Tangier disease³³ Tangier disease
a rare autosomal recessive disorder with near-absent HDL, cholesterol-laden macrophage deposits, and accelerated atherosclerosis. rs2853579 operates at a far subtler level — it is a common synonymous coding variant within ABCA1 exon 15 whose effect on HDL arises not from any protein change but from its co-inheritance with nearby regulatory variation that modulates how much ABCA1 the liver produces.

The Mechanism

rs2853579 sits at chr9:104,828,991 (GRCh38) within the coding sequence of ABCA1 at transcript position c.2040 on NM_005502.4. The ABCA1 gene is transcribed from the minus strand; genome files report the plus strand, where the reference allele is G and the minor allele is T. The G>T change corresponds to a C>A substitution on the coding strand — an ATC→ATA codon change that encodes isoleucine at position 680 in both cases (p.Ile680Ile). This synonymous⁴⁴ synonymous
a variant that changes the DNA sequence but not the resulting amino acid — sometimes called a "silent" mutation variant therefore cannot alter ABCA1 protein function directly. Any influence on HDL-C must arise through linkage disequilibrium⁵⁵ linkage disequilibrium
LD — the tendency for nearby alleles to be inherited together; a tag SNP statistically "marks" a causal variant nearby without being functionally responsible itself with a causal regulatory element.

The ABCA1 locus contains several intronic enhancers governing hepatic expression. Richardson et al.⁶⁶ Richardson et al.
Richardson et al. Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism. PLOS One, 2019 identified that the intronic variant rs2575875 creates an allele-specific STAT3⁷⁷ Signal Transducer and Activator of Transcription 3 — a transcription factor that activates gene expression in response to cytokines and growth factors in the liver binding site that loops physically to the ABCA1 promoter and drives hepatic transporter expression. Multiple GWAS tag SNPs across the ABCA1 locus — including rs4149268, rs1883025, and rs2853579 — show overlapping HDL-C associations consistent with tagging the same or related regulatory haplotype. The G allele of rs2853579 marks the lower-expression haplotype; the T allele marks the higher-expression haplotype.

The Evidence

The association was identified in a large EHR-based GWAS⁸⁸ EHR-based GWAS
Hoffmann TJ et al. A large electronic-health-record-based genome-wide study of serum lipids. Nature Genetics, 2018 of 94,674 ancestrally diverse Kaiser Permanente participants using longitudinal untreated lipid measurements. rs2853579-G was associated with decreased HDL-C (β = −0.046 mmol/L, p = 6×10⁻¹⁶) and decreased total cholesterol (β = −0.053 mmol/L, p = 1×10⁻¹⁹) at genome-wide significance. A second analysis from the same dataset found p = 2×10⁻²⁰ for HDL-C with β = −0.044 mmol/L per G allele — equivalent to roughly −1.7 mg/dL per allele. For context, typical HDL-C ranges from 40 to 80 mg/dL, so the per-allele effect is modest but statistically robust and biologically coherent.

Population frequencies from gnomAD show remarkable ancestry variation: the T allele (higher HDL) is rare in Europeans (~12%) and South Asians (~15%) but reaches 66% in East Asian populations and 45% in African populations. In East Asia, T is the major allele — meaning the lower-HDL GG genotype is actually the minor one in that ancestry. ClinVar classifies this variant as benign for Tangier disease and hypoalphalipoproteinemia, consistent with the GWAS data showing small common-variant effects rather than the large functional disruptions that characterize those disorders.

Practical Actions

For most carriers of the common GG genotype (~73% of the global population), this variant represents the population-typical baseline for ABCA1-driven HDL production. The most actionable information at this locus is your measured HDL-C. The per-allele effect of ~1.7 mg/dL for the T allele translates to approximately +3.4 mg/dL for TT homozygotes — a meaningful directional tendency but one that is easily matched or exceeded by lifestyle factors: regular aerobic exercise raises HDL by 3–6 mg/dL in most people; eliminating trans fats adds 2–4 mg/dL; replacement of saturated fat with monounsaturated fat (olive oil, avocado, nuts) provides additional benefit.

Carriers of the rare TT genotype (~2% in Europeans, ~44% in East Asians) have a genetically favorable signal at this locus. Confirmed low HDL despite the favorable TT genotype would warrant a broader workup of other lipid-modifying variants, dietary patterns, and metabolic factors.

Interactions

rs2853579 sits within the same ABCA1 gene as rs4149268 and rs1883025, two other intronic variants previously associated with HDL-C in GWAS. Whether they represent independent regulatory signals or partial correlates of the same haplotype has not been fully resolved at the individual-study level. The R219K missense variant (rs2230806, ABCA1) alters protein-level cholesterol efflux capacity through a distinct mechanism from regulatory tag SNPs and represents an independent functional layer. Carriers of other low-HDL variants — such as CETP (rs708272) or LIPC variants — can compound the rs2853579 G-allele effect through additive lipid pathway disruption.

Alpha-1 antitrypsin (AAT) is the body's primary defense against neutrophil elastase, a powerful enzyme¹¹ powerful enzyme
Neutrophil elastase is released by white blood cells during inflammation and can break down elastin, the protein that gives lung tissue its elasticity that can destroy lung tissue if left unchecked. The Z allele (Glu342Lys) is the most common genetic variant causing severe AAT deficiency, affecting approximately 1 in 2,000 to 3,500 births²² 1 in 2,000 to 3,500 births
The ZZ genotype occurs in about 1:2,000-3,500 newborns in populations of European descent, though most remain undiagnosed. This single amino acid change — glutamic acid to lysine at position 342 — causes the protein to misfold and polymerize inside liver cells, leading to both lung disease (from lack of AAT in circulation) and liver disease (from toxic accumulation in the liver).

The Mechanism

The Z variant creates a structural instability³³ structural instability
The substitution of acidic glutamic acid with basic lysine at position 342 disrupts protein folding, causing AAT molecules to link together (polymerize) in the endoplasmic reticulum of liver cells that prevents normal secretion from liver cells. Instead of being released into the bloodstream, approximately 85% of Z variant AAT gets retained in hepatocytes as large protein polymers. ZZ homozygotes have serum AAT levels at only 10-20% of normal⁴⁴ 10-20% of normal
Normal AAT levels are approximately 20-53 µM (150-350 mg/dL); ZZ individuals typically have <11 µM, while MZ heterozygotes have approximately 60% of normal levels. This dual pathology — loss of function in the lungs and toxic gain of function in the liver — makes the Z allele unique among common genetic disorders.

The molecular consequence is a loss of protease-antiprotease balance in the lungs. Neutrophil elastase, normally kept in check by AAT, breaks down elastin and collagen in alveolar walls⁵⁵ alveolar walls
The tiny air sacs in the lungs where oxygen and carbon dioxide exchange occurs. Without sufficient AAT protection, this leads to panlobular emphysema — progressive destruction of lung tissue starting in the bases and spreading throughout the lungs.

The Evidence

The clinical significance of the Z allele is well established through decades of research. ZZ homozygotes face 80-100% risk of developing emphysema⁶⁶ ZZ homozygotes face 80-100% risk of developing emphysema
Based on ClinGen classification and long-term follow-up studies of diagnosed individuals and 10-15% risk of liver cirrhosis by adulthood. The risk is dramatically modified by environmental factors, particularly smoking⁷⁷ smoking
Smoking increases COPD risk in ZZ individuals and accelerates disease onset by 10-15 years compared to non-smokers.

MZ heterozygotes (carriers) were long considered "safe," but recent large population studies have overturned this assumption. A meta-analysis of six studies⁸⁸ meta-analysis of six studies
Dahl et al., European Respiratory Journal, 2005 found MZ smokers have 3.26-fold increased odds of COPD compared to MM individuals (95% CI: 1.24-8.57). Non-smoking MZ carriers do not appear to have increased lung disease risk, demonstrating a clear gene-environment interaction⁹⁹ gene-environment interaction
The triple combination of MZ genotype, smoking, and occupational dust/fume exposure compounds risk beyond any single factor.

For liver disease, a large cohort study¹⁰¹⁰ large cohort study
Published in Hepatology, 2018 found MZ heterozygotes have 1.53 odds ratio for cirrhosis compared to MM individuals, with risk amplified by higher BMI. Among ZZ children, 18% develop clinically recognized liver abnormalities and 2.4% develop cirrhosis in childhood¹¹¹¹ 2.4% develop cirrhosis in childhood
Swedish newborn screening study following 200,000 children, though most ZZ children remain clinically well.

Practical Implications

The Z allele is one of the most actionable genetic findings in genomics. Smoking avoidance is critical — the difference between a normal lifespan and severe disability by age 40. Augmentation therapy¹²¹² Augmentation therapy
Intravenous infusions of pooled human AAT, administered weekly at 60 mg/kg, raise serum levels into the protective range is available for ZZ individuals with established lung disease, and has been shown to slow emphysema progression in randomized controlled trials¹³¹³ randomized controlled trials
The RAPID trial demonstrated significant reduction in lung density loss: 1.5 g/L/year with treatment vs 2.6 g/L/year with placebo (p=0.07). The therapy is not curative but can meaningfully slow disease progression when started early.

For MZ carriers, counseling about smoking and occupational exposures is essential. Vapors, gases, dusts, and fumes¹⁴¹⁴ Vapors, gases, dusts, and fumes
Agricultural chemicals, welding fumes, silica dust, and other occupational exposures interact with MZ genotype to increase COPD risk common in agriculture, welding, and industrial settings pose added risk. Air pollution and long-term ozone exposure are also independent risk factors for lung impairment in both ZZ and MZ individuals.

Liver monitoring is warranted for all ZZ individuals and should be considered for MZ carriers with other liver disease risk factors. The variable clinical presentation means some ZZ individuals develop life-threatening liver disease in childhood while others remain asymptomatic into adulthood. Genetic counseling and family testing is recommended — first-degree relatives of diagnosed individuals should be offered testing to enable preventive measures.

Interactions

The Z allele interacts significantly with the S allele (rs17580)¹⁵¹⁵ S allele (rs17580)
The S allele (Glu264Val) causes milder AAT deficiency, with serum levels at 60% of normal. SZ compound heterozygotes have AAT levels intermediate between MZ and ZZ, with 20-50% risk of emphysema depending on smoking exposure. The combination warrants similar preventive counseling as for MZ carriers, particularly regarding smoking avoidance.

Beyond SERPINA1, other genes modify lung disease risk in AAT deficiency. Cryptic SERPINA1 haplotypes¹⁶¹⁶ Cryptic SERPINA1 haplotypes
Six haplotypes with a common backbone of five SNPs were found to increase COPD risk 6-50 fold, the highest risk reported for COPD genetics. Variants in SERPINE2 (encoding another protease inhibitor) are associated with emphysema severity in autopsy studies.

The relationship between AAT deficiency and liver disease in other chronic conditions is complex. Z allele carriage increases liver disease risk in cystic fibrosis¹⁷¹⁷ Z allele carriage increases liver disease risk in cystic fibrosis
4.17-fold increased odds of CF-related liver disease and chronic hepatitis C, suggesting that AAT deficiency exacerbates liver injury from other causes. However, hepatocellular carcinoma risk in ZZ cirrhosis is lower (0.88%/year) than in cirrhosis from viral hepatitis or NASH, challenging earlier assumptions about cancer risk.

A compound implication for MZ + active smoking + occupational dust/fume exposure would be warranted given the documented three-way interaction, with recommendations for aggressive exposure reduction and earlier pulmonary function monitoring.

Your MST1 gene encodes macrophage-stimulating protein (MSP), a critical regulator of innate immune responses¹¹ innate immune responses
The first-line defense system that responds to pathogens without prior exposure to bacterial challenges in the gut. The rs3197999 variant causes an arginine-to-cysteine substitution at position 689 (R689C) in the protein, located within a critical receptor-binding domain that determines how effectively MSP activates immune cells.

This variant sits at the intersection of immune surveillance and inflammatory disease. It's one of the most consistently replicated genetic risk factors²² It's one of the most consistently replicated genetic risk factors
Confirmed across multiple populations and study designs for inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC), appearing in genome-wide association studies with odds ratios of 1.20 for IBD and 1.51 for PSC. Unlike many genetic variants that simply reduce protein function, the Cys689 variant actually enhances certain aspects of macrophage activity—a gain of function that paradoxically increases inflammation risk.

The Mechanism

MSP is secreted primarily by the liver and circulates in blood as an inactive precursor. When cleaved by proteases at sites of tissue injury or bacterial invasion, it becomes biologically active and binds to the RON receptor tyrosine kinase on macrophages, epithelial cells, and other immune cells³³ epithelial cells, and other immune cells
RON is expressed in tissues throughout the body but especially abundant in gut-associated immune cells. This triggers signaling cascades that regulate chemotaxis (cell migration toward infection sites), phagocytosis (engulfment of bacteria), and cytokine production.

The R689C substitution occurs in the serine protease homology domain⁴⁴ occurs in the serine protease homology domain
This domain forms the receptor-binding surface but is catalytically inactive—MSP is a "dead" protease that retained its binding structure of the MSP β-chain. Functional studies using macrophage-like cell lines showed that the Cys689 variant significantly increases the stimulatory effect⁵⁵ significantly increases the stimulatory effect
Enhanced chemotaxis and proliferation compared to wild-type Arg689 of MSP on chemotaxis and proliferation. This gain of function suggests the variant creates a hyperactive immune response—macrophages migrate more aggressively and respond more vigorously to bacterial signals.

Paradoxically, individuals with the AA genotype have approximately 10-fold lower MSP binding affinity⁶⁶ approximately 10-fold lower MSP binding affinity
Measured in receptor-binding assays to RON and profoundly decreased serum MSP levels. The mechanism appears to involve altered protein stability or secretion efficiency. So the variant simultaneously increases cellular responsiveness when MSP binds but reduces overall circulating MSP—a complex functional profile that may dysregulate normal immune homeostasis in the gut.

The Evidence

The initial discovery came from gene-centric mapping⁷⁷ The initial discovery came from gene-centric mapping
Rather than unbiased GWAS, this study specifically targeted chromosome 3p21 based on prior linkage evidence of the 3p21 IBD linkage region in 2008. Fisher and colleagues identified rs3197999 with P=3.62×10⁻⁶ in a combined screen of 1,020 IBD patients and replication in 745 additional cases. The variant showed association with both Crohn's disease and ulcerative colitis.

A 2008 meta-analysis⁸⁸ A 2008 meta-analysis
Barrett et al., combining data from three studies with 3,230 Crohn's cases and 4,829 controls confirmed the association with genome-wide significance (P=1.15×10⁻¹², OR=1.20). A parallel study in 3,133 ulcerative colitis patients and 4,494 controls replicated the finding (combined P=3.8×10⁻⁹).

The variant's role extends beyond classic IBD. A 2011 genome-wide association study in primary sclerosing cholangitis⁹⁹ A 2011 genome-wide association study in primary sclerosing cholangitis
Melum et al., 715 Scandinavian and German PSC cases vs 2,962 controls identified rs3197999 as one of two non-HLA susceptibility loci with P=1.1×10⁻¹⁶ and OR=1.51. PSC is a chronic cholestatic liver disease characterized by bile duct inflammation and frequently co-occurs with IBD. Homozygous AA carriers also show increased risk¹⁰¹⁰ Homozygous AA carriers also show increased risk
OR=1.97 for overall cholangiocarcinoma, OR=1.84 for PSC-unrelated biliary tract cancer of cholangiocarcinoma, the feared cancer complication of chronic bile duct inflammation.

Gene-gene interaction analysis¹¹¹¹ Gene-gene interaction analysis
In a Chinese Crohn's disease cohort of 1,590 cases and 1,478 controls identified significant interactions between MST1 and JAK2, IL23R, and PTGER4—all genes involved in inflammatory signaling pathways. This suggests MST1 participates in broader networks regulating mucosal immunity rather than acting in isolation.

A 2024 pediatric study¹²¹² A 2024 pediatric study
367 pediatric IBD patients (197 Crohn's, 170 ulcerative colitis) found the CC genotype was positively associated with systemic steroid use in Crohn's disease and more common in female CD patients, suggesting the variant may influence disease severity or treatment requirements beyond simple susceptibility.

Practical Actions

If you carry one or two copies of the A allele, your genetic profile suggests a heightened inflammatory response to gut bacterial challenges. This doesn't guarantee you'll develop IBD—most carriers remain healthy—but it warrants attention to gut barrier health and inflammatory triggers.

Dietary patterns matter significantly¹³¹³ Dietary patterns matter significantly
Multiple studies show Mediterranean diet adherence reduces IBD risk and disease activity. The Mediterranean diet's benefits likely operate through multiple mechanisms: omega-3 fatty acids modulate inflammatory signaling, polyphenols reduce oxidative stress, and fiber feeds beneficial bacteria that produce short-chain fatty acids (SCFAs) like butyrate, which strengthen gut barrier integrity. Higher adherence to Mediterranean diet¹⁴¹⁴ Higher adherence to Mediterranean diet
In first-degree relatives of Crohn's patients, a population already at higher genetic risk was associated with reduced intestinal inflammation and lower risk of later-onset Crohn's disease.

Monitoring inflammatory markers can catch subclinical inflammation before symptoms appear. C-reactive protein (CRP) and fecal calprotectin¹⁵¹⁵ C-reactive protein (CRP) and fecal calprotectin
Calprotectin is more specific for intestinal inflammation and correlates better with endoscopic findings than CRP are the most validated biomarkers in IBD. Fecal calprotectin <250 μg/g identifies mucosal healing with 94% sensitivity, and rising levels can predict relapse earlier than clinical symptoms.

Probiotics have mixed evidence in IBD. For ulcerative colitis specifically¹⁶¹⁶ For ulcerative colitis specifically
Not for Crohn's disease, where most studies show no benefit over placebo, certain strains show promise: Escherichia coli Nissle 1917 for maintenance of remission, and VSL#3 (a multi-strain probiotic) for inducing remission in mild to moderately active UC. VSL#3 is the only probiotic with strong evidence¹⁷¹⁷ VSL#3 is the only probiotic with strong evidence
Particularly for pouchitis, an inflammatory condition of the surgically created intestinal pouch in common IBD practice.

Interactions

The rs3197999 variant lies in a complex genomic region on chromosome 3p21 that contains 10 genes within a 336 kb associated interval. Notably, it's in linkage disequilibrium¹⁸¹⁸ Notably, it's in linkage disequilibrium
Almost complete cosegregation of minor alleles, D'=0.60, r²=0.35 with rs1050450 in GPX1 (glutathione peroxidase 1), which causes a Pro198Leu substitution that reduces GPx-1 antioxidant enzyme activity. Some researchers have proposed that GPX1, rather than MST1, might be the pathophysiologically relevant gene at this locus.

The functional distinction is important: MST1 R689C affects innate immune activation (macrophage chemotaxis and bacterial response), while GPX1 Pro198Leu affects antioxidant capacity (ability to neutralize reactive oxygen species produced during inflammation). Both mechanisms could plausibly contribute to IBD pathogenesis. It's possible that the true causal variant is neither rs3197999 nor rs1050450 but another variant in linkage disequilibrium with both, or that both variants independently contribute to disease risk through complementary pathways. Given the proximity and LD structure, individuals with the MST1 A allele often also carry the GPX1 Leu198 allele, potentially compounding inflammatory susceptibility through both enhanced immune activation and reduced antioxidant defense.

Gene-gene interaction studies have identified significant epistasis between MST1 and several inflammatory pathway genes. The MST1–JAK2 interaction was replicated across original and validation datasets, and MST1 showed consistent interactions with IL23R (interleukin-23 receptor, a validated IBD susceptibility gene targeted by biologics like ustekinumab) and PTGER4 (prostaglandin E receptor 4, involved in inflammatory signaling). These interactions suggest that MST1 genetic effects may be amplified or modified by variation in other immune genes, and that personalized risk assessment should eventually incorporate multi-locus profiles rather than single-SNP analysis.

The FAAH gene encodes fatty acid amide hydrolase¹¹ fatty acid amide hydrolase
an enzyme that breaks down anandamide, your brain's natural "bliss molecule", which binds to the same receptors as THC from cannabis. The rs324420 variant changes a single amino acid at position 129 from proline to threonine, making the enzyme more vulnerable to breakdown. Carriers of the A allele produce less stable FAAH enzyme, resulting in elevated anandamide levels throughout the brain and body²² elevated anandamide levels throughout the brain and body.

This common variant occurs in approximately 38% of Europeans (33% heterozygous AC, 5% homozygous AA), with markedly higher frequencies in African populations (~45%) and lower in East Asians (~10%)³³ markedly higher frequencies in African populations (~45%) and lower in East Asians (~10%). The geographic distribution has led researchers to investigate whether this variant influences not just individual psychology but national happiness levels across cultures⁴⁴ national happiness levels across cultures.

The Mechanism

The Pro129Thr substitution doesn't change FAAH's catalytic activity — the enzyme still breaks down anandamide at normal rates when it's present. The critical difference is protein stability⁵⁵ protein stability. The threonine variant (A allele) is more sensitive to proteolytic degradation, meaning cells produce approximately 50% less FAAH enzyme in AA homozygotes compared to CC individuals. This leads to chronically elevated anandamide signaling through CB1 cannabinoid receptors, primarily in the amygdala, prefrontal cortex, and hippocampus — brain regions central to fear processing, stress response, and emotional regulation⁶⁶ fear processing, stress response, and emotional regulation.

Elevated anandamide acts like a natural anxiolytic, dampening the amygdala's threat response and enhancing fronto-amygdala connectivity. In neuroimaging studies, A-allele carriers show reduced amygdala activation when viewing threatening faces⁷⁷ A-allele carriers show reduced amygdala activation when viewing threatening faces and faster fear extinction learning — the ability to unlearn fear associations after a threat is no longer present.

The Evidence

Fear extinction and trauma response: Multiple fMRI studies demonstrate that A-allele carriers show enhanced fear extinction recall⁸⁸ Multiple fMRI studies demonstrate that A-allele carriers show enhanced fear extinction recall, the neurobiological foundation of exposure therapy for PTSD and anxiety disorders. In a study of 55 healthy adults, AC heterozygotes showed significantly greater extinction recall compared to CC individuals, with distinct neural activation patterns in the ventromedial prefrontal cortex. This suggests the A allele may confer resilience to trauma-related symptoms, though one large veteran study (N=949) found no protective effect against PTSD development after military deployment⁹⁹ one large veteran study (N=949) found no protective effect against PTSD development after military deployment.

Pain sensitivity: Women with the AA genotype undergoing breast cancer surgery reported significantly less sensitivity to cold pain¹⁰¹⁰ Women with the AA genotype undergoing breast cancer surgery reported significantly less sensitivity to cold pain (β = −1.48, 95% CI −2.14 to −0.8) and required less postoperative analgesia. A rare case report documented a Scottish woman with complete pain insensitivity, anxiety immunity, and accelerated wound healing¹¹¹¹ a Scottish woman with complete pain insensitivity, anxiety immunity, and accelerated wound healing, who carried both the AA genotype and a rare deletion in FAAH-OUT, a regulatory pseudogene.

Mood and well-being: The relationship with happiness is complex. A longitudinal study of 2,822 individuals found that each A-allele was associated with lower subjective well-being scores¹²¹² A longitudinal study of 2,822 individuals found that each A-allele was associated with lower subjective well-being scores at both timepoints (B: −0.52, p = 0.007). However, cross-national studies show countries with higher A-allele frequencies report greater national happiness¹³¹³ countries with higher A-allele frequencies report greater national happiness, with Ghana, Nigeria, and Mexico ranking highest. The paradox may reflect that chronically elevated anandamide leads to CB1 receptor downregulation over time, potentially disrupting normal reward processing.

Substance use: The A allele shows divergent effects across substances¹⁴¹⁴ divergent effects across substances. For cannabis, AA individuals have roughly half the dependence rate of CC carriers (11% vs 26%) and report less subjective pleasure from marijuana — likely because they already have elevated endogenous cannabinoid tone. However, for alcohol, A-allele carriers with European ancestry show more severe alcohol dependence¹⁵¹⁵ A-allele carriers with European ancestry show more severe alcohol dependence when they do develop problems (13 more binge drinking days over a 90-day period), potentially via an indirect pathway through lower subjective well-being. The A allele has also been associated with increased risk of methamphetamine dependence in Malaysian populations¹⁶¹⁶ increased risk of methamphetamine dependence in Malaysian populations (OR 2.0-3.7 depending on ethnicity).

Athletic performance: Elite volleyball and rink-hockey players with the A allele were 2-3 times more likely to achieve "super athlete" status¹⁷¹⁷ Elite volleyball and rink-hockey players with the A allele were 2-3 times more likely to achieve "super athlete" status, possibly due to enhanced stress coping and pain tolerance during training and competition. However, contradictory evidence exists, with some studies showing the AA genotype more common in sedentary individuals than elite athletes.

Practical Implications

If you carry the A allele, your endocannabinoid system is running at a higher baseline, with downstream effects on how you process fear, pain, stress, and reward. This may make you more resilient to acute stressors and physical pain, but potentially more vulnerable to mood disturbances if you experienced childhood trauma, which can interact with the A allele to increase anxiety and depression risk¹⁸¹⁸ interact with the A allele to increase anxiety and depression risk.

For mental health treatment, A-allele carriers may respond particularly well to exposure-based therapies for anxiety and PTSD, given the enhanced fear extinction consolidation. FAAH inhibitors — drugs designed to mimic the A-allele effect — are in clinical trials for anxiety disorders and showed promise in a 12-week trial for social anxiety¹⁹¹⁹ promise in a 12-week trial for social anxiety, though results have been mixed.

For pain management, AA individuals may require less analgesia for acute pain but should still discuss post-operative pain plans with providers, as individual variation is substantial. The reduced pain sensitivity doesn't eliminate pain entirely.

For substance use, recognize that if you have the A allele, cannabis will likely be less appealing and addictive, but alcohol may pose greater risk if you develop problematic use patterns, particularly if you also struggle with low mood.

Interactions

The FAAH rs324420 variant interacts with other endocannabinoid and stress-response genes. CNR1 rs2180619 (cannabinoid receptor 1) and CRHR1 rs110402 (corticotropin-releasing hormone receptor 1) have been studied for interactions with FAAH in stress response, though a large veteran study found no significant gene-gene interaction effects²⁰²⁰ a large veteran study found no significant gene-gene interaction effects. The COMT rs4680 variant (which affects dopamine metabolism) has been shown to interact with FAAH rs324420 in modulating placebo analgesia response²¹²¹ interact with FAAH rs324420 in modulating placebo analgesia response.

Early life stress represents a critical environmental interaction. Individuals with the A allele who experienced repetitive childhood trauma show significantly higher anxiety and depression scores²²²² Individuals with the A allele who experienced repetitive childhood trauma show significantly higher anxiety and depression scores compared to CC carriers with similar trauma exposure, suggesting chronically elevated anandamide during neurodevelopment may disrupt normal CB1 receptor function and long-term stress response systems.

Your blood carries von Willebrand factor (VWF)¹¹ von Willebrand factor (VWF)
A large multimeric protein that anchors platelets to damaged vessel walls and escorts Factor VIII through the circulation; elevated VWF is an independent VTE risk factor and Factor VIII continuously, but the liver clears these proteins at a rate that determines their plasma concentration. What regulates clearance? In large part, a molecular sugar coating. Sialic acid residues attached to the outer glycan chains of VWF and Factor VIII shield them from asialoglycoprotein receptors (ASGPR) on hepatocytes — the liver's galactose-recognition machinery that flags aging or under-glycosylated proteins for destruction. The ST3GAL4 enzyme is responsible for adding α2,3-linked sialic acids to these protective glycan termini. Variants near the ST3GAL4 gene alter this sialylation activity, which in turn shifts steady-state VWF and Factor VIII levels — and therefore VTE risk.

The Mechanism

ST3GAL4 (ST3 beta-galactoside alpha-2,3-sialyltransferase 4)²² ST3GAL4 (ST3 beta-galactoside alpha-2,3-sialyltransferase 4)
One of a family of six ST3GAL enzymes that catalyze transfer of sialic acid in the α2,3 linkage onto N- and O-linked glycans is expressed in endothelial cells and hepatocytes, where it acts on newly synthesized VWF and Factor VIII. Fully sialylated VWF has reduced affinity for ASGPR on liver macrophages and hepatocytes; removing sialic acid from VWF dramatically accelerates its hepatic clearance³³ removing sialic acid from VWF dramatically accelerates its hepatic clearance
Byrne et al. 2025 showed that enzymatic desialylation of both plasma-derived and recombinant VWF produced identical, rapid clearance regardless of other glycan differences.

The rs35257264 T allele is located in an intronic region overlapping the ST3GAL4 genomic locus. It acts as a cis-regulatory variant — most likely influencing ST3GAL4 expression or splicing in endothelial cells — rather than altering the enzyme's amino acid sequence directly. The net effect of the T allele is an upward shift in steady-state sialylation activity, meaning VWF and Factor VIII are more effectively protected from clearance, circulate longer, and accumulate at higher plasma concentrations. The coagulation balance tilts toward clotting.

The Evidence

The VWF/FVIII-elevating effect of ST3GAL4 variants was established in a 2016 ARIC cohort analysis: Song et al. studied 12,117 participants⁴⁴ Song et al. studied 12,117 participants
Multi-ethnic ARIC cohort; associations held in both European American and African American ancestry groups after adjustment for ABO blood group, age, BMI, hypertension, and diabetes and identified three ST3GAL4 intronic SNPs significantly associated with both VWF antigen levels and Factor VIII activity.

The VTE connection was subsequently confirmed in two large independent GWAS meta-analyses. Thibord et al. 2022⁵⁵ Thibord et al. 2022
Cross-ancestry meta-analysis of 30 cohorts; 81,669 VTE cases including European, African, and Hispanic ancestry populations; identified 135 independent genomic loci identified the ST3GAL4 region among 135 independent VTE risk loci. Ghouse et al. 2023⁶⁶ Ghouse et al. 2023
Nature Genetics; 81,190 VTE cases and 1,419,671 controls across six cohorts; 93 significant loci, 62 previously unreported; polygenic risk score performance comparable to monogenic thrombophilia testing replicated the ST3GAL4 region in a non-overlapping cohort with 93 total loci, confirming it as a reproducible signal.

A 2024 GWAS of 45,289 participants for circulating Factor VIII and VWF levels⁷⁷ circulating Factor VIII and VWF levels
de Vries et al. 2024; identified 7 novel loci for FVIII including ST3GAL4 at genome-wide significance P < 5×10⁻⁹ identified ST3GAL4 as a novel genome-wide significant locus for Factor VIII levels, closing the mechanistic loop between the GWAS VTE signal and the VWF/FVIII axis.

For clinical context: a systematic review and meta-analysis of 15 studies⁸⁸ a systematic review and meta-analysis of 15 studies
Lowe et al. 2023; 5,327 VTE cases; pooled OR for FVIII quartile 4 vs. quartile 1: 3.92 (95% CI 1.61–5.29) found that Factor VIII levels above the 90th percentile are associated with a 3-fold higher VTE risk, confirming that elevated FVIII — the proximal mechanism by which ST3GAL4 T allele exerts its effect — is a dose-dependent independent VTE risk factor.

The effect size for rs35257264 itself is modest (OR approximately 1.21 per T allele), which is typical for common regulatory GWAS variants acting through quantitative trait changes. This places it in the context of a contributing factor rather than a high-penetrance thrombophilia like Factor V Leiden or prothrombin G20210A.

Practical Implications

The T allele's relevance is highest when added to other thrombotic risk — surgery, immobility, oral contraceptives, pregnancy, or co-inherited thrombophilias. In these settings, the additional nudge toward elevated VWF/FVIII that the T allele provides compounds with environmental and genetic co-factors. Carriers should ensure providers are aware of this variant when planning high-risk situations, and may benefit from VWF or Factor VIII level testing to understand their baseline quantitative risk.

There are no drugs or supplements that specifically modulate ST3GAL4 activity in clinical practice. Standard VTE prevention measures apply with heightened attention to provocation management.

Interactions

The ST3GAL4 T allele acts through the same VWF/FVIII quantitative axis as other clotting factor loci. Its effect is most clinically relevant when combined with other thrombophilic variants — particularly [Factor V Leiden (rs6025, F5 R506Q) | Activated protein C resistance; ~5% carrier frequency in Europeans; 3-8 fold VTE risk for heterozygotes] or [prothrombin G20210A (rs1799963) | ~1-3% carrier frequency; 2-5 fold VTE risk], which impair anticoagulant mechanisms at a different node of the coagulation cascade. Combined carrier status for ST3GAL4 T allele plus either classical thrombophilia would compound risks additively or possibly synergistically.

ABO blood group is a critical co-determinant of VWF levels: blood group O individuals have ~25% lower VWF than non-O individuals through a separate glycosylation-clearance mechanism. The ST3GAL4 T allele effect operates independently of ABO (Song et al. 2016 adjusted for ABO) but their absolute VWF levels are determined by both factors together.

Deep within the long arm of chromosome 9 sits a genetic locus that helps explain why rheumatoid arthritis clusters in families and why some patients respond poorly to the most effective treatments available. The TRAF1-C5 locus¹¹ The TRAF1-C5 locus
TRAF1 encodes TNF receptor-associated factor 1, a scaffold protein inside immune cells that amplifies inflammatory NF-kB signaling; C5 encodes complement component 5, a protein that drives joint inflammation through the complement cascade at 9q33.3 contains two genes, each contributing to the inflammatory cascade that erodes joints in autoimmune arthritis. rs3761847 is an intronic variant in TRAF1 that serves as the principal GWAS tag SNP for this entire locus — its G allele marks a chromosomal haplotype that increases susceptibility to rheumatoid arthritis by approximately 32% per copy.

The Mechanism

rs3761847 sits in an intron of TRAF1 on chromosome 9 (GRCh38 position 120,927,961), with the TRAF1 gene encoded on the minus strand. The variant itself is not a coding change — it does not alter any amino acid. Instead, it acts as a linkage disequilibrium tag²² linkage disequilibrium tag
A tag SNP marks a haplotype block: it travels with nearby functional variants through generations because recombination between them is rare, making the tag SNP a reliable proxy for the causal variant(s) for a haplotype that alters TRAF1 expression in immune cells.

TRAF1 protein is a key intracellular scaffold in the TNF receptor signaling pathway. When TNF-alpha binds its receptor on immune cells, TRAF1 is recruited to the receptor complex and modulates the downstream activation of NF-kB³³ NF-kB
Nuclear factor kappa-light-chain-enhancer of activated B cells — a master transcription factor that switches on hundreds of pro-inflammatory genes including cytokines, chemokines, and adhesion molecules that drive joint inflammation. Higher TRAF1 expression — associated with the G-allele haplotype — amplifies NF-kB activation in CD14+ monocytes and other inflammatory cells, tilting the immune response toward persistent inflammation rather than resolution. Studies in Japanese RA patients found significantly elevated TRAF1 protein in monocytes from G-allele carriers, providing a direct mechanistic link between genotype and cellular phenotype.

The neighboring C5 gene contributes through a separate mechanism: complement component 5 is cleaved to C5a in the synovial fluid of inflamed joints, where it drives macrophage activation and inflammatory cytokine release. The G-allele haplotype at rs3761847 spans both genes, potentially influencing both TRAF1-mediated NF-kB amplification and complement-driven synovial inflammation.

The Evidence

The foundational discovery came from Plenge et al. (2007)⁴⁴ Plenge et al. (2007)
NEJM genome-wide study analyzing 317,503 SNPs in 1,522 anti-CCP-positive RA cases and 1,850 controls from NARAC and EIRA cohorts, replicated in an additional 997 cases and 1,777 controls, who identified rs3761847 as the top signal at the TRAF1-C5 locus with an odds ratio of 1.32 (95% CI 1.23–1.42, p = 4×10⁻¹⁴) in anti-CCP-positive rheumatoid arthritis — one of the most significant non-HLA genetic associations for RA at that time. Crucially, the effect was strongest in seropositive (anti-CCP-positive) disease, which is the most genetically driven, erosive form of RA.

A meta-analysis by Song et al. (2014)⁵⁵ meta-analysis by Song et al. (2014)
Immunological Investigations meta-analysis encompassing 24 studies with 22,682 RA cases and 23,493 controls across European and Asian populations confirmed the European association (OR 1.156, 95% CI 1.006–1.327 per G allele) while finding no statistically significant effect in Asian cohorts (OR 1.049, p = 0.333). This ethnic divergence is explained by differences in linkage disequilibrium⁶⁶ linkage disequilibrium
LD refers to the non-random co-inheritance of alleles; if the causal variant is in strong LD with rs3761847 in Europeans (r²=0.67) but weaker LD in Asians (r²=0.37), the tag SNP is more informative in the former between rs3761847 and the actual functional variant(s) in the two population groups.

Replication in East Asian populations confirmed the locus itself matters: Zhu et al. (2011)⁷⁷ Zhu et al. (2011)
BMC Medical Genetics, 576 RA patients and 689 controls in Han Chinese found significant association of rs3761847 (p = 0.0018, OR 1.28) in their Han Chinese cohort, independent of anti-CCP and RF concentrations — demonstrating that the genetic effect at this locus is not simply a proxy for serological status.

Beyond susceptibility, the TRAF1-C5 locus influences treatment outcomes. Canhão et al. (2015)⁸⁸ Canhão et al. (2015)
Biomedical Research International, Southern European RA patients on anti-TNF therapy found that the G risk allele at rs3761847 predicted poor response to anti-TNF biologics in multivariate analyses. This is mechanistically coherent: if the G haplotype drives higher TRAF1 expression and stronger NF-kB activation, those same pathways may counteract TNF blockade.

Practical Actions

For G-allele carriers — particularly GG homozygotes — the key clinical implications are threefold: early awareness of seropositive RA symptoms, proactive monitoring of relevant biomarkers (anti-CCP antibodies and CRP), and awareness that standard anti-TNF biologic therapy may be less effective for GG carriers. These individuals may benefit from JAK inhibitors or IL-6 pathway inhibitors as preferential first-line biologic options when conventional DMARDs fail, since these targets operate downstream of or parallel to TRAF1-mediated NF-kB signaling.

The G allele is approximately 43% globally and 42% in Europeans, making it common rather than rare. Most Europeans carry at least one copy. GG homozygotes (~18% in Europeans) carry the highest genetic burden at this locus. Seronegative RA patients should note that the evidence for this locus is substantially weaker outside the anti-CCP-positive disease subtype.

Interactions

rs3761847 sits in a pathway heavily influenced by other autoimmune susceptibility loci. The TNFAIP3 locus on chromosome 6q23 — specifically rs6920220 and rs13207033 — encodes A20, the primary brake on NF-kB signaling that TRAF1 activates. Carriers of both a TRAF1-C5 G risk allele and TNFAIP3 risk variants face a double hit: amplified NF-kB signaling (via TRAF1) combined with impaired NF-kB termination (via A20 deficiency). The PTPN22 rs2476601 variant (R620W) represents a third independent RA risk signal that alters T-cell receptor signaling thresholds, and its combination with TRAF1-C5 G-allele carriage further elevates seropositive RA risk.

The PTPN22 gene region on chromosome 1p13 is one of the most studied loci in autoimmune genetics. Most attention focuses on the R620W missense variant (rs2476601), which alters T-cell signaling threshold and drives risk for rheumatoid arthritis, type 1 diabetes, and lupus. But haplotype analyses have revealed that the locus harbors multiple independent signals¹¹ multiple independent signals
Deep sequencing and haplotype studies of 37+ PTPN22 variants identified secondary association signals that are statistically independent of R620W and tag different disease patterns. rs3789604 is one such secondary variant — a synonymous change in the neighboring RSBN1 gene that marks a distinct haplotype block associated specifically with early-onset psoriasis and Graves' disease, rather than with the RA/T1D pattern driven by R620W.

RSBN1 (round spermatid basic protein 1) encodes a protein involved in chromatin regulation, but rs3789604's disease associations operate through linkage disequilibrium with nearby PTPN22 regulatory elements²² linkage disequilibrium with nearby PTPN22 regulatory elements
rs3789604 is a synonymous coding change — it doesn't alter the RSBN1 protein. Its clinical significance comes from being a tag SNP that marks a chromosomal haplotype block also covering PTPN22 regulatory regions. Changes in the haplotype's regulatory architecture modulate PTPN22 expression or splice isoform ratios in immune cells. PTPN22 encodes LYP (lymphoid tyrosine phosphatase), a potent suppressor of T-cell receptor signaling that sets the activation threshold for both T and B lymphocytes.

The Mechanism

rs3789604 sits at GRCh38 chr1:113,812,320 within an exon of RSBN1, which is transcribed on the minus strand. The plus-strand alleles are T (reference, ~83% frequency) and G (alternate, ~17%). The nucleotide change is synonymous in RSBN1 — it does not alter the arginine at codon 31 — but rs3789604 resides in the same chromosomal neighborhood as PTPN22 and is in linkage disequilibrium³³ linkage disequilibrium
LD means alleles co-occur more frequently than chance because of their proximity on the chromosome — rs3789604 and nearby variants travel together through generations, so any one serves as a proxy for the others with multiple PTPN22 intronic and upstream variants. The G allele marks a specific haplotype block (documented in scleritis studies as the "TTATACGCG" haplotype) that is enriched in several inflammatory conditions.

The functional effect is inferred to operate through non-coding regulatory changes in the PTPN22 gene: altered promoter activity, enhancer function, or splicing signals that modulate how much LYP protein is produced in immune cells. Lower LYP activity (from reduced expression) lowers the activation threshold for T cells, increasing the likelihood of autoreactive responses. Higher LYP activity (from elevated expression) may conversely impair normal immune responses. The exact direction depends on the specific haplotype and disease context — which explains why the G allele shows risk in psoriasis but some Asian studies report different directional effects for Graves' disease.

The Evidence

The strongest evidence comes from psoriasis. Smith et al. 2008⁴⁴ Smith et al. 2008
Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol 2008 found rs3789604 significantly associated with Type I (early-onset) psoriasis (P=0.0002) in a UK cohort of 647 cases and 566 controls, replicated in a combined dataset of 900 cases and 2,590 controls. Crucially, R620W showed no association with psoriasis in the same samples — demonstrating that rs3789604 tags a distinct functional signal, not the classic R620W haplotype.

This finding was independently replicated by Li et al. 2009⁵⁵ Li et al. 2009
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol 2009 in a combined meta-analysis of 2,823 psoriasis cases and 4,066 controls (P=3.45×10⁻⁵), one of the largest psoriasis genetics datasets assembled at that time. The consistent signal across two independent study designs in different populations substantially strengthens the association.

For Graves' disease, data show population heterogeneity. Ichimura et al. 2008⁶⁶ Ichimura et al. 2008
Associations of PTPN22 gene polymorphisms with susceptibility to Graves' disease in a Japanese population. Thyroid 2008 found the A allele (T on plus strand, the reference) significantly elevated in Japanese GD patients (OR=1.45, P=0.0085; 414 patients, 231 controls). In contrast, a Chinese study (Gu et al. 2010, PMID 19438904) found the AA genotype correlated with reduced GD risk. This apparent contradiction likely reflects differences in haplotype background⁷⁷ haplotype background
The same rs3789604 allele may sit on chromosomes with different flanking PTPN22 variants in different populations, meaning the allele tags different regulatory configurations in Japanese vs Chinese vs European genomes.

For rheumatoid arthritis, Wesoly et al. 2007⁸⁸ Wesoly et al. 2007
The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population. Rheumatology 2007 found no independent RA association for rs3789604 (P=0.134), confirming that at least in Europeans, R620W is the dominant signal and rs3789604 does not independently tag RA risk.

Practical Implications

The clinical takeaway from rs3789604 is primarily about psoriasis and related spondyloarthropathy risk, operating through the PTPN22 locus independently of R620W. Carriers of one or two G alleles face modestly elevated risk for early-onset psoriasis. Psoriasis affects about 2–3% of the global population and can transition to psoriatic arthritis in approximately 30% of cases — a destructive inflammatory arthropathy that may present years after skin disease onset. Catching psoriasis early enables topical and systemic interventions that reduce the progression to joint involvement.

The scleritis and Graves' disease signals are secondary findings with more limited or population-specific evidence. Carriers should be aware that autoimmune conditions at the PTPN22 locus tend to cluster — having one PTPN22-region variant increases the probability of other inflammatory conditions in the same pathway.

Interactions

rs3789604 is in close proximity to rs1217414 (an intronic PTPN22 variant also associated with psoriasis and ankylosing spondylitis) and was found to interact in the psoriasis signal. Smith et al. found that carrying risk alleles at both rs1217414 and rs3789604 showed a stronger combined association (P=0.002) than either alone, consistent with a shared haplotype effect. Both variants are largely independent of R620W (rs2476601), which primarily drives RA and T1D risk. Together, rs3789604 and rs1217414 define a psoriasis/spondyloarthropathy-specific PTPN22 haplotype distinct from the R620W haplotype that governs RA and T1D risk.

Every time your immune cells encounter diacylated lipopeptides — the molecular calling-card of mycoplasma, staphylococcal lipoproteins, and certain gram-positive bacteria — they rely on a precise molecular handshake between Toll-like Receptor 2 (TLR2)¹¹ Toll-like Receptor 2 (TLR2)
TLR2 is the central scaffold for bacterial lipopeptide sensing; it forms heterodimers with either TLR1 (for triacylated lipopeptides) or TLR6 (for diacylated lipopeptides), activating NF-κB and driving TNF-α, IL-6, and IL-12 production and TLR6²² TLR6
Toll-like Receptor 6, encoded at chromosome 4p14; forms obligate heterodimers with TLR2 and is distinguished from TLR1 by a blocked lipid channel that restricts ligand recognition to diacylated — not triacylated — lipopeptides. The rs3796508 Val327Met variant substitutes a structurally conservative valine with a bulkier, polar methionine at position 327 in TLR6's extracellular leucine-rich repeat (LRR) domain — a change that SIFT and PolyPhen independently predict to be damaging to protein function.

This variant is extremely rare in European populations (T allele ~0.2%) but reaches a frequency of approximately 6% in East Asian populations (gnomAD), making it clinically relevant primarily for individuals of East Asian ancestry. It has no ClinVar entry, but published functional predictions and emerging association data across multiple disease contexts — colorectal cancer, allergic rhinitis, smoking-related disease — consistently point to meaningful functional consequences in the TLR2/TLR6 signaling arm of innate immunity. Its placement here in the autoimmune-inflammation category captures TLR6's role not only in infectious defense but in the chronic, low-grade inflammatory processes that contribute to autoimmune pathology.

The Mechanism

The 2009 crystal structure of the TLR2/TLR6 heterodimer (Kang et al., Immunity 2009³³ Kang et al., Immunity 2009
PMID 19931471; first crystal structure of TLR2/TLR6 bound to diacylated lipopeptide; determined at 2.1 Å resolution) revealed the molecular basis for TLR6's unique specificity. Unlike TLR1, which accommodates a third fatty acid chain in an open lipid channel, TLR6 has its corresponding channel blocked by two conserved phenylalanines — physically preventing triacylated lipopeptide binding and enforcing diacylated specificity. When these phenylalanines are mutated, TLR2/TLR6 loses its diacyl-exclusivity. The compensating structural feature is a dimerization interface that is 80% larger than TLR2/TLR1, stabilising the heterodimer through extensive hydrophobic contacts in the absence of a full three-chain lipid anchor.

Position 327 falls within the leucine-rich repeat domain of TLR6 that forms part of this enlarged dimerization interface and contributes to the extracellular geometry that coordinates diacylated lipopeptide presentation. Valine at position 327 is a hydrophobic residue well-suited to packing into the hydrophobic dimerization interface; methionine is larger and introduces a flexible sulphur-containing side chain. The Val327Met substitution likely perturbs local packing of the LRR domain, potentially altering the geometry of TLR2/TLR6 heterodimer assembly and reducing signaling efficiency upon ligand engagement. SIFT (deleterious) and PolyPhen-2 (probably damaging) predictions, reported in the colorectal cancer association study by Semlali et al. 2019⁴⁴ Semlali et al. 2019
PMID 31281474, support the inference of functional disruption.

The Evidence

Compared to TLR6 Ser249Pro (rs5743810) — the more extensively studied variant in the same gene — rs3796508 Val327Met has a much smaller published literature, and no study has directly measured the impact of Met327 on TLR2/TLR6 heterodimer formation or NF-κB activation in primary cells. The evidence base is emerging and largely association-derived.

The most direct disease association comes from a Saudi Arabian colorectal cancer case-control study⁵⁵ colorectal cancer case-control study
115 CRC cases, 102 healthy controls; genotyped by TaqMan assay by Semlali et al. (2019). In the global analysis, rs3796508 showed no significant association with CRC risk overall, but in subgroup analyses the Val/Met heterozygous genotype demonstrated a protective effect in males (OR=0.095, p=0.034) and in individuals over 57 years⁶⁶ protective effect in males (OR=0.095, p=0.034) and in individuals over 57 years
these are suggestive findings from a small study (n=217) and require independent replication. The same paper noted that TLR6 expression was significantly reduced in colon cancer tissue versus normal colon (p<0.001), positioning TLR6 as a potential tumour-suppressive innate immune sensor in the gut. Reduced TLR2/TLR6 signalling from Met327 could plausibly impair this innate surveillance.

In an inflammatory context, a 2026 Chinese Han study (Wang et al., Sci Rep 2026⁷⁷ Wang et al., Sci Rep 2026
PMID 41663697; 992 AR patients versus 992 healthy controls; primary focus on NFKB1 variants with TLR6 rs3796508 as a secondary finding) found that rs3796508 contributed to increased allergic rhinitis (AR) risk specifically in women. This sex-specific effect is consistent with reports of sex-dimorphic TLR6 phenotypes in other variants (notably rs5743810 Ser249Pro, where cardiovascular and leprosy associations show sex-specific patterns). The AR finding is notable because it suggests Met327 may shift TLR2/TLR6 responses in a direction that promotes type-2 (Th2) allergic inflammation — potentially through altered NF-κB dynamics that affect the Th1/Th2 balance during early immune development and sensitisation.

A smoking study (Kohailan et al., Onco Targets Ther 2016⁸⁸ Kohailan et al., Onco Targets Ther 2016
PMID 27920557; 177 smokers vs 126 non-smokers; Saudi population) examined rs3796508 among TLR6 variants in smokers, proposing the Val327Met variant as a potential index for smoking-related disease susceptibility. Tobacco smoke contains lipopolysaccharide- and lipopeptide-like compounds that chronically activate TLR2/TLR6; a damaging variant at position 327 could blunt this response — a mechanism consistent with altered inflammatory signalling in smoking-exposed airways.

Practical Implications

The evidence for rs3796508 is emerging and requires cautious interpretation. The variant is predicted damaging by two independent computational tools, which provides a biological prior for functional effects on TLR2/TLR6 signalling. However, no functional cellular studies have directly measured NF-κB output, cytokine production, or heterodimer formation efficiency in cells carrying the Met327 allele — these experiments are needed to validate computational predictions.

For carriers — predominantly individuals of East Asian descent (~6%) where the variant reaches population significance — the actionable implications centre on monitoring contexts where TLR2/TLR6 competence matters: gut barrier function (TLR6 plays a role in colonic innate surveillance), respiratory allergy (sex-specific AR risk increase in women), and chronic inflammatory conditions where TLR2/TLR6 pathway tone modulates disease expression.

The TLR2/TLR6 pathway also serves as a critical interface between commensal gut bacteria and mucosal immune regulation. The beneficial gut bacterium Faecalibacterium prausnitzii⁹⁹ Faecalibacterium prausnitzii
a major short-chain fatty acid producer and key modulator of gut immune homeostasis; low in IBD patients signals through TLR2/TLR6 to prime regulatory T cells — a pathway that could be impaired by reduced Met327 signalling.

Interactions

TLR6 operates exclusively through TLR2 (rs5743708). The TLR2 R753Q variant independently impairs TLR2 signalling from the intracellular TIR domain; any individual carrying both rs5743708 (TLR2 R753Q) and rs3796508 (TLR6 Val327Met) faces potential compound reduction of TLR2/TLR6 output from two separate structural points. The Ser249Pro variant (rs5743810) in TLR6 modulates NF-κB activation efficiency from the extracellular domain; individuals with both rs3796508 and rs5743810 risk alleles on the same TLR6 molecule (in cis) would carry two independent damaging changes in the same receptor — a scenario that warrants investigation in populations where both alleles are present (East Asian populations carry both at detectable frequencies). TLR1 (rs5743618) handles the triacylated lipopeptide arm of pattern recognition and operates independently of TLR6.

Selenoprotein P (SELENOP, formerly SEPP1) is the primary selenium transport protein in human plasma. Unlike most proteins, which are built from the standard 20 amino acids, SELENOP incorporates selenocysteine¹¹ selenocysteine
the 21st amino acid, structurally similar to cysteine but with selenium replacing sulfur — it gives selenoproteins their exceptional antioxidant power at 10 positions. SELENOP accounts for roughly 50–60% of all plasma selenium and is the main vehicle by which the liver ships selenium to peripheral tissues — brain, testes, kidney, and thyroid among them. rs3877899 changes a single amino acid at position 234 of the protein, swapping alanine for threonine, and this substitution measurably alters how much selenium your body successfully delivers.

The Mechanism

SELENOP circulates as a mixture of isoforms. The full-length 60-kDa form contains all 10 selenocysteine residues and binds the apoER2 receptor (LRP8) on target cells, enabling receptor-mediated uptake of selenium into tissues. Shorter truncated isoforms containing six or fewer selenocysteine residues cannot bind apoER2 and are therefore poor selenium donors to tissues. The Ala234Thr substitution falls within a region of SELENOP that influences this isoform balance. In colorectal cancer patients, the GG coding genotype (CC plus-strand) combined with a 3'UTR variant in rs7579 was associated with decreased expression of the full-length 60-kDa isoform²² colorectal cancer patients, the GG coding genotype (CC plus-strand) combined with a 3'UTR variant in rs7579 was associated with decreased expression of the full-length 60-kDa isoform
Short SP et al. Free Radic Biol Med. 2018, suggesting the variant's effects on isoform ratios are context-dependent.

A randomized dietary intervention in 170 Danish adults aged 50–74³³ randomized dietary intervention in 170 Danish adults aged 50–74
Kopp TI et al. Genes Nutr. 2018 provided the clearest functional evidence: participants who ate 1,000 g of selenium-rich fish and mussels weekly for 26 weeks showed a genotype-dependent rise in plasma SELENOP. CC homozygotes achieved plasma selenoprotein P levels averaging 4.68 ng/mL higher than T-allele carriers at week 26 (95% CI −8.49 to −0.871, p=0.018). The T allele blunts the protein-level response to dietary selenium — meaning T carriers absorb selenium but synthesize or retain SELENOP less efficiently.

The Evidence

Selenium transport efficiency: The Kopp et al. RCT (n=170) is the most direct human evidence that the T allele compromises SELENOP upregulation in response to selenium intake. The CC genotype more effectively converts dietary selenium into circulating SELENOP, the protein responsible for distributing it.

Pregnancy and GPx response: A UK cohort of 230 pregnant women by Mao et al. 2016⁴⁴ Mao et al. 2016
Mao J et al. Am J Clin Nutr. 2016 found that T-allele carriers (coding A allele) maintained blood selenium better during gestation (p=0.005, explaining 8% of variance) and showed greater glutathione peroxidase-3 (GPx3) activity increases in response to selenium supplementation (p=0.01). This suggests the T allele may partially reroute selenium toward GPx synthesis rather than SELENOP.

Prostate cancer: A Chicago cohort study of prostate cancer patients by Ekoue et al. 2018⁵⁵ Ekoue et al. 2018
Ekoue DN et al. Prostate. 2018 found that men homozygous for the TT genotype (coding AA, Thr/Thr) had nearly 6-fold higher odds of treatment failure within 2 years of surgery (OR=5.75, 95% CI 1.09–30.5, p=0.021) compared to CC (Ala/Ala) homozygotes. This was independent of serum selenium levels, suggesting the functional isoform produced by the Ala234Thr variant — rather than circulating selenium per se — influences cancer progression.

Retinopathy of prematurity: In a cohort of 173 premature infants (gestational age ≤32 weeks), Strauss et al. 2023⁶⁶ Strauss et al. 2023
Strauss E et al. Int J Mol Sci. 2023 found the rs3877899 A allele (coding A = plus-strand T) significantly associated with advanced retinopathy of prematurity requiring treatment (OR=1.8, p=0.045). TT homozygote infants showed OR=7.0 for treatment-requiring ROP and OR=13.6 for treatment failure (p=0.005). The proposed mechanism is impaired antioxidant protection during critical retinal vascularization due to reduced selenium bioavailability.

Metabolic effects: A Brazil nut supplementation RCT in 130 healthy volunteers by Donadio et al. 2018⁷⁷ Donadio et al. 2018
Donadio JLS et al. Eur J Nutr. 2018 found that CT+TT carriers had significantly lower fasting glucose compared to CC carriers, suggesting the Thr234 protein variant may interact with selenoprotein P's emerging role in glucose metabolism.

Practical Implications

The T allele does not simply lower selenium — it changes how selenium is packaged and delivered. T-allele carriers may benefit from ensuring consistent selenium intake through food sources with high selenomethionine bioavailability, since selenomethionine (from Brazil nuts, fish, eggs) is incorporated non-specifically into all proteins and provides a buffer that selenocysteine-dependent SELENOP cannot. Selenium supplementation above 200 mcg/day carries toxicity risk regardless of genotype; targeting the 55–200 mcg/day range through diet is appropriate for T carriers.

Interactions

The companion variant rs7579 in SELENOP (a 3'UTR variant at c.*14G>A) interacts with rs3877899 to influence isoform expression in colorectal cancer patients. The combined GG(rs3877899) + GA(rs7579) genotype was associated with the greatest reduction in full-length 60-kDa SELENOP. rs3877899 also functionally interacts with the selenium pathway partner rs1050450 (GPX1 Pro198Leu) — both variants modulate how effectively dietary selenium is converted into active selenoproteins, and their combined effect on cancer risk is an active area of research. The SELENOP-GPX4 axis (rs713041) is a third interaction point, as GPX4 competes with SELENOP for selenium incorporation and affects ferroptosis susceptibility.

Myosin heavy chains are the molecular motors that drive muscle contraction. The MYH gene family encodes 15 isoforms, each specialized for different muscle types: cardiac myosins power the heart, skeletal myosins drive limb movement, and a handful of unconventional isoforms serve more specialized roles. MYH15 falls into this last group. Expressed primarily in extraocular muscles (which control eye movement) and muscle spindles¹¹ muscle spindles
proprioceptive sensory organs embedded in skeletal muscle, it is not a classic cardiac or smooth muscle myosin. Yet genetic studies from the mid-to-late 2000s flagged rs3900940 in MYH15 as a possible contributor to coronary heart disease risk — a finding that remains intriguing but incompletely explained.

The Mechanism

rs3900940 lies on chromosome 3 at position 108,428,881 (GRCh38). Because MYH15 is transcribed from the minus strand, the plus-strand reference allele T corresponds to a coding-strand A at position 3313 of the transcript (NM_014981.3). The alternate C allele on the plus strand produces a coding-strand G, changing codon 1105 from Thr (ACT) to Ala (GCT) — the p.Thr1105Ala substitution. Threonine at position 1105 sits in the C-terminal tail domain²² C-terminal tail domain
the region of myosin heavy chain responsible for filament assembly and interaction with other structural proteins. Replacing a polar, phosphorylatable threonine with a nonpolar alanine could in principle alter filament packing or post-translational regulation, but the functional consequence of this specific substitution has not been directly characterized.

How a variant in an extraocular/spindle myosin might influence coronary disease risk is mechanistically unclear. One hypothesis: MYH15 may have low-level expression in vascular smooth muscle or coronary endothelium that has been missed by bulk transcriptomic surveys but contributes to vessel wall mechanics. A 2014 study found that intronic MYH15 variants associate with abnormal coronary flow reserve in men³³ intronic MYH15 variants associate with abnormal coronary flow reserve in men
Yoshino et al., Coronary Artery Disease 2014 with odds ratios of 2.27–2.60, the authors noting that "further studies are needed to clarify how MYH15 might be involved in vascular biology." Another possibility is that rs3900940 is in linkage disequilibrium with a nearby causal variant in a different gene. Given the limited mechanistic work, the association currently rests on epidemiological evidence without a confirmed molecular pathway.

The Evidence

The original genetic risk signal emerged from prospective cohort work. Bare et al. (2007)⁴⁴ Bare et al. (2007) examined five genetic variants in the Atherosclerosis Risk in Communities (ARIC) cohort of 9,129 white adults. Participants carrying the highest-risk combination of all five variants (including rs3900940) had a 57% increased hazard for incident coronary heart disease (HR 1.57, 95% CI 1.21–2.04, P = 0.001). However, individual effect estimates for rs3900940 were not reported separately in the published paper — the variant was evaluated only as part of a combined polygenic score, limiting interpretation of its independent contribution.

The stroke connection came from the Vienna Stroke Registry. Luke et al. (2009)⁵⁵ Luke et al. (2009) tested CHD-linked SNPs in 562 stroke cases and 815 controls, finding that rs3900940 in MYH15 was among those associated with noncardioembolic stroke: OR 1.31 (90% CI 1.07–1.60). Noncardioembolic stroke includes large-artery atherosclerotic stroke and small-vessel disease — phenotypes that share pathophysiological features with coronary atherosclerosis. The same group extended this analysis to the Cardiovascular Health Study, finding that rs3900940's prespecified risk allele showed nominal association with ischemic stroke in white participants (one-sided P < 0.05), though this study specifically flagged seven SNPs including MYH15 without providing individual ORs for each.

The coronary microvascular angle comes from a 2014 candidate-gene study of 643 patients evaluated for coronary flow reserve (CFR). Yoshino et al.⁶⁶ Yoshino et al. found that two intronic MYH15 variants (rs4855559 and rs7630352, distinct from rs3900940) showed striking male-specific associations with impaired CFR (OR ≈ 2.3–2.6, SNP-sex interaction P < 0.001) with no significant signal in women. This sex-specific pattern suggests MYH15 may interact with androgen-driven vascular biology, but rs3900940 was not among the variants tested in that study.

Taken together, the evidence is consistent but not strong. Multiple small-to-medium studies point in the same direction, but the variant has never been a standalone genome-wide significant hit, effect sizes are modest, and the biological mechanism connecting an extraocular myosin to coronary risk is unresolved. The evidence level is therefore emerging rather than moderate or strong.

Practical Actions

The modest, replicated association between rs3900940 and coronary/stroke risk means that CC homozygotes have a somewhat elevated probability of atherosclerotic cardiovascular disease. The effect size (OR ~1.3 for one copy of the risk allele) is comparable to many common cardiovascular risk variants — meaningful at a population level, modest at an individual level. The most actionable implication is that CC carriers should prioritize surveillance of established cardiovascular risk factors (LDL, blood pressure, glucose) rather than treating this variant as a high-penetrance finding.

TC heterozygotes carry an intermediate risk. The variant appears to act additively, with each copy of the C allele contributing approximately proportionally to risk.

Interactions

rs3900940 was originally evaluated alongside four other variants — rs20455 in KIF6, rs7439293 in PALLD, rs2298566 in SNX19, and rs1010 in VAMP8 — in a combined genetic risk score for coronary heart disease. When all five risk alleles are present, the combined effect (HR 1.57) exceeds what any single variant contributes. This multi-variant interaction context suggests that rs3900940 may be most informative when interpreted in conjunction with these co-validated CHD risk markers.